MedTrace Logo

Epstein-Barr Virus and Cancer Risks

NCT06203314 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100000

Last updated 2024-01-12

No results posted yet for this study

Summary

The goal of this prospective cohort study is to investigate the associations between Epstein-Barr Virus (EBV) antibody levels and the risk of overall and site-specific cancer types in Southern China. The main questions it aims to answer are:

Question 1: In addition to the established EBV-associated cancer types, such as lymphomas, nasopharyngeal carcinoma, and stomach cancer, whether EBV is associated with other cancer types? Question 2: What's the cancer burden attributed to EBV in Southern China?

Conditions

Interventions

OTHER

Diagnostic test: EBV antibody tests

Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.

Sponsors & Collaborators

  • Wuzhou Red Cross Hospital

    collaborator OTHER

  • Zhongshan People's Hospital, Guangdong, China

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-01
Primary Completion
2024-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06203314 on ClinicalTrials.gov